LT3256580T - Cisteino proteazė - Google Patents

Cisteino proteazė

Info

Publication number
LT3256580T
LT3256580T LTEPPCT/EP2016/053052T LT16053052T LT3256580T LT 3256580 T LT3256580 T LT 3256580T LT 16053052 T LT16053052 T LT 16053052T LT 3256580 T LT3256580 T LT 3256580T
Authority
LT
Lithuania
Prior art keywords
cysteine protease
cysteine
protease
Prior art date
Application number
LTEPPCT/EP2016/053052T
Other languages
English (en)
Lithuanian (lt)
Inventor
Christian Kjellman
Sofia JARNUM
Emma NORDAHL
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of LT3256580T publication Critical patent/LT3256580T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
LTEPPCT/EP2016/053052T 2015-02-12 2016-02-12 Cisteino proteazė LT3256580T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Publications (1)

Publication Number Publication Date
LT3256580T true LT3256580T (lt) 2022-10-10

Family

ID=52781456

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2016/053052T LT3256580T (lt) 2015-02-12 2016-02-12 Cisteino proteazė

Country Status (23)

Country Link
US (5) US10696959B2 (show.php)
EP (2) EP3256580B1 (show.php)
JP (1) JP6961486B2 (show.php)
KR (1) KR102524613B1 (show.php)
CN (2) CN114231512B (show.php)
AU (2) AU2016217800B2 (show.php)
BR (1) BR112017017284A2 (show.php)
CA (1) CA2976003A1 (show.php)
CL (1) CL2017002065A1 (show.php)
CO (1) CO2017009061A2 (show.php)
DK (1) DK3256580T3 (show.php)
EA (1) EA035130B1 (show.php)
ES (1) ES2927234T3 (show.php)
GB (1) GB201502306D0 (show.php)
IL (1) IL253938B (show.php)
LT (1) LT3256580T (show.php)
MX (1) MX390806B (show.php)
MY (1) MY188696A (show.php)
PL (1) PL3256580T3 (show.php)
PT (1) PT3256580T (show.php)
SG (1) SG11201706346QA (show.php)
WO (1) WO2016128558A1 (show.php)
ZA (1) ZA201705113B (show.php)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
AU2019247746B2 (en) 2018-04-03 2024-08-15 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
KR20210006358A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 안 조직을 표적으로 하기 위한 바이러스 벡터
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
EP4038194A1 (en) 2019-10-04 2022-08-10 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
KR20220140537A (ko) 2020-02-14 2022-10-18 울트라제닉스 파마수티컬 인코포레이티드 Cdkl5 결핍 장애를 치료하기 위한 유전자 요법
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
JP7795790B2 (ja) 2020-06-05 2026-01-08 上海宝済薬業股▲ふん▼有限公司 酵素とウィルスとの薬物組成物及びその使用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素IdeEの突然変異体
IL300717A (en) 2020-08-19 2023-04-01 Sarepta Therapeutics Inc ADENO-related virus vectors for the treatment of RETT syndrome
CA3195177A1 (en) 2020-10-07 2022-04-14 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i)
EP4323015A4 (en) 2021-04-16 2025-10-22 Askbio Inc RATIONALLY POLYPLOID AAV VIRIONS CROSS THE BLOOD-BRAIN BARRIER AND TRIGGER A REDUCED HUMORAL RESPONSE
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
CN119013396A (zh) 2021-11-15 2024-11-22 汉莎生物制药股份有限公司 增强过继性细胞转移免疫疗法的方法
KR20240123827A (ko) 2021-12-16 2024-08-14 상하이 바오 파마슈티컬스 컴퍼니 리미티드 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체
EP4450080A4 (en) 2021-12-22 2025-12-10 Shanghai Bao Pharmaceuticals Co Ltd USE OF A MUTANT OF AN IMMUNOGLOBULIN-DEGRADING ENZYME IDEA
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN118853710A (zh) * 2022-11-08 2024-10-29 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
JP2026501731A (ja) 2023-01-06 2026-01-16 サイズミック セラピューティク インコーポレイテッド プロテアーゼ変異体及びその使用
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
CA2432525C (en) 2000-12-21 2012-11-27 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
EP1576964A4 (en) * 2002-11-29 2008-06-11 Morinaga Milk Industry Co Ltd PROTEASE INHIBITOR
EP1601770B1 (en) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
ES2380950T3 (es) * 2005-06-09 2012-05-21 Hansa Medical Ab Uso de la proteinasa IdeS ( de S, pyogenes) para tratar enfermedades autoinmunitarias y rechazo de injerto
US7544577B2 (en) * 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
EP2190984B1 (en) * 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
US20110020403A1 (en) 2007-12-13 2011-01-27 Bengt Guss immunizing composition
WO2009080278A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Stability testing of antibodies
CN102308216B (zh) * 2009-02-09 2014-07-09 罗切格利卡特公司 免疫球蛋白糖基化模式分析
CA2799136A1 (en) 2010-05-26 2011-12-01 Intervacc Ab Vaccine against streptococcal infections based on recombinant proteins
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Also Published As

Publication number Publication date
MX2017010390A (es) 2017-12-07
KR102524613B1 (ko) 2023-04-21
EP3256580A1 (en) 2017-12-20
US20230357741A1 (en) 2023-11-09
US20220170004A1 (en) 2022-06-02
GB201502306D0 (en) 2015-04-01
AU2021266293B2 (en) 2024-10-03
NZ733959A (en) 2024-07-26
EA035130B1 (ru) 2020-04-30
CA2976003A1 (en) 2016-08-18
US12359183B2 (en) 2025-07-15
CL2017002065A1 (es) 2018-04-02
US20180023070A1 (en) 2018-01-25
ES2927234T3 (es) 2022-11-03
MX390806B (es) 2025-03-21
IL253938A0 (en) 2017-10-31
US11214784B2 (en) 2022-01-04
CO2017009061A2 (es) 2018-01-16
WO2016128558A1 (en) 2016-08-18
PL3256580T3 (pl) 2022-11-28
ZA201705113B (en) 2024-01-31
US10696959B2 (en) 2020-06-30
EP4108768A1 (en) 2022-12-28
IL253938B (en) 2020-01-30
AU2021266293A1 (en) 2021-12-09
CN114231512B (zh) 2025-02-14
KR20170116137A (ko) 2017-10-18
EA201791773A1 (ru) 2018-02-28
DK3256580T3 (en) 2022-10-03
JP6961486B2 (ja) 2021-11-05
AU2016217800B2 (en) 2021-08-12
BR112017017284A2 (pt) 2018-04-17
PT3256580T (pt) 2022-10-03
SG11201706346QA (en) 2017-09-28
MY188696A (en) 2021-12-23
CN107532156A (zh) 2018-01-02
EP3256580B1 (en) 2022-07-06
US20200283749A1 (en) 2020-09-10
US11667905B2 (en) 2023-06-06
US20250304937A1 (en) 2025-10-02
AU2016217800A1 (en) 2017-08-10
JP2018506286A (ja) 2018-03-08
CN114231512A (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
LT3256580T (lt) Cisteino proteazė
IL253939A0 (en) cysteine protease
DK3212780T3 (da) Serinprotease
DK3627029T3 (da) Manipulationssikret låg
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3212662T3 (da) Serinproteaser
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
DK3305788T3 (da) Janus-kinase-hæmmer
DK3212781T3 (da) Serinproteaser
DK3331529T3 (da) Muskarinagonister
DK3386954T3 (da) Dimere kontrastmidler
DK3310450T3 (da) Olie-vand-separator
DK3142386T3 (da) Tætningsørestykke
DK3270930T3 (da) Præeklampsi
DK3292136T3 (da) Penicillin-g-acylaser
DK3271981T3 (da) Tætning
DE112015006486A5 (de) Inkubationsrinne
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE102015206660A8 (de) Plattenaufteilanlage
DE112015005906A5 (de) Gurtschlossbringer
EP3424943A4 (en) PEPTIDE
DE112016005599A5 (de) Strahlungsgrill
DE102015000551A8 (de) Rotationszerstäuberturbine